Cover Image

PP 3.10 - 00168 Vpr synergizes with vorinostat to prevent HIV-1 latency establishment

Saved in:

Bibliographic Details
Main Authors:	C. Lewis (Author), D. Margolis (Author), E. Browne (Author)
Format:	Book
Published:	Elsevier, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial
by: J. Alagaratnam, et al.
Published: (2019)

PP 1.33 - 00167 Integrated single-cell multi-omic profiling of HIV latency reversal
by: A. Manickam, et al.
Published: (2022)

PP 1.4 - 00037 Histone decrotonylation uniquely regulates HIV-1 transcription and can be modulated to control HIV-1 latency
by: T.L. Simermeyer, et al.
Published: (2022)

Vorinostat-An overview
by: Aditya Kumar Bubna
Published: (2015)

Epigenomic characterisation of a primary cell model of HIV latency
by: E. Browne, et al.
Published: (2019)

PP 4.12 - 00141 Enhancement of IL15/IL15RA signaling in immune cells using CRISPR-dCas9-VPR platform
by: S. Brancazio, et al.
Published: (2022)

McCloskey, S. (Ed.)(2014). Development Education in Policy and Practice. London: Palgrave Macmillan, 310 pp.
by: Sarah Carrica-Ochoa
Published: (2014)

Single cell analysis of HIV latency reveals diverse proviral and host cell behaviour
by: E.P. Browne, et al.
Published: (2017)

PP 1.10 - 00069 Isotretinoin enhances IL-15 mediated HIV latency reversal and reduces the inducible latent reservoir
by: J. Howard, et al.
Published: (2022)

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015)

PP 5.4 - 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022)

The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
by: C. Gay, et al.
Published: (2019)

Unprimed CD8 lymphocytes promote the establishment of HIV latency in CD4 T cells
by: L. Franchitti, et al.
Published: (2019)

Single-cell transcriptomics to evaluate HIV latency establishment in primary CD4 T cells
by: L. De Armas, et al.
Published: (2017)

Targeted screens identify new chromatin regulators of HIV latency
by: A.-M. Turner, et al.
Published: (2017)

PP 1.1 - 00009 TB-associated microenvironment promotes HIV latency in CD4+ T cells
by: G. Duette, et al.
Published: (2022)

PP 2.9 - 00125 Impact of latency reversal agents on estrogen receptor alpha gene and protein expression
by: C. Ceriani, et al.
Published: (2022)

Induction of HIV from latency by a novel molecule
by: N.M. Archin, et al.
Published: (2015)

Using single-cell analysis and a primary model of HIV to study latency establishment and reactivation
by: L. De Armas, et al.
Published: (2019)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

PP 1.39 - 00086 The level of cell activation is associated with the pre-integrative latency of HIV linear DNA
by: H.M. Roux, et al.
Published: (2022)

OP 2.7 - 00057 The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells
by: D.C. Copertino, et al.
Published: (2022)

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

P1 Contribution of lncRNAs in the establishment of HIV latency in central memory CD4 T Cells
by: Wim Trypsteen, et al.
Published: (2017)

PP 1.3 - 00022 Signaling pathways that activate P-TEFb to reverse HIV latency in CD4+ T cells
by: U. Mbonye, et al.
Published: (2022)

PP 2.13 - 00160 Enhancing Tolerability and Efficacy of Latency Reversing Agents in "Kick and Kill" HIV Cure Approaches
by: J. Moran, et al.
Published: (2022)

PP 1.22 - 00120 Suppression of CD4+ T-cell-intrinsic immunity by HIV-1 latency-reversing HDACi
by: J. Kazmierski, et al.
Published: (2022)

PP 2.7 - 00093 Modeling HIV-1 Pathogenesis and Latency in iPSC-Derived Human Cerebral Organoids
by: J. Crater, et al.
Published: (2022)

OA1-1 Impact of vorinostat treatment of non-Hodgkin's lymphoma on HIV-1 latent reservoir
by: A. Capoferri, et al.
Published: (2017)

PP 1.11 - 00075 Selective nuclear retention of spliced and unspliced HIV-1 mRNAs following latency reversal
by: E. Honeycutt, et al.
Published: (2022)

10 The interferon-inducible restriction factor TRIM22 contributes to HIV-1 latency
by: F. Turrini, et al.
Published: (2016)

Pattern of odontogenic infections at a tertiary hospital in tehran, iran: a 10-year retrospective study of 310 patients.
by: Fereydoun Pourdanesh, et al.
Published: (2013)

OP 1.5 - 00046 P400/Tip60 chromatin remodeling complex in HIV transcription and latency establishment
by: L. Mori, et al.
Published: (2022)

The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis
by: Long He, et al.
Published: (2021)

PP 3.11 - 00171 The chromatin insulator CTCF inhibits HIV gene expression
by: S. Burgos, et al.
Published: (2022)

Laparoscopic Sacropexy: A Retrospective Analysis of the Subjective Outcome in 310 Cases
by: B. Bojahr, et al.
Published: (2012)

Correction to Lancet Glob Health 2023; 11: e310-11
Published: (2023)

A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
by: Eugène D.M.B. Kroon, et al.
Published: (2020)

Pharmacological interactions: Synergism, or not synergism, that is the question
by: Luigino Calzetta, et al.
Published: (2021)

SMAC mimetics are potent latency reversal agents with single agent and combination activity ex vivo
by: R.M. Dunham, et al.
Published: (2017)